PRIME MEDICINE INC. - COMMON STOCK

Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

18 Mar 2025 06:00:00 By Nasdaq GlobeNewswire

Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates

28 Feb 2025 07:00:00 By Nasdaq GlobeNewswire

Prime Medicine to Present at TD Cowen 45th Annual Health Care Conference

24 Feb 2025 07:00:00 By Nasdaq GlobeNewswire

Prime Medicine to Present at 43rd Annual J.P. Morgan Healthcare Conference

07 Jan 2025 07:00:01 By Nasdaq GlobeNewswire

Prime Medicine Reports Third Quarter 2024 Financial Results and Provides Business Updates

12 Nov 2024 15:00:00 By Nasdaq GlobeNewswire

Prime Medicine to Participate in Upcoming Investor Conferences

06 Nov 2024 15:00:00 By Nasdaq GlobeNewswire

Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson’s Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress

24 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson’s Disease, at Upcoming Scientific Meetings

15 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Prime Medicine Unveils Strategically Focused Pipeline

30 Sep 2024 06:01:00 By Nasdaq GlobeNewswire

Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies

30 Sep 2024 06:00:00 By Nasdaq GlobeNewswire

Prime Medicine to Participate in Upcoming Investor Conferences

28 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Prime Medicine Reports Second Quarter 2024 Financial Results and Provides Business Updates

08 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Prime Medicine to Present at Upcoming Investor Conferences

30 May 2024 07:00:00 By Nasdaq GlobeNewswire

Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

13 May 2024 07:00:00 By Nasdaq GlobeNewswire

Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates

10 May 2024 07:00:00 By Nasdaq GlobeNewswire

Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD)

08 May 2024 07:00:00 By Nasdaq GlobeNewswire

Prime Medicine to Participate in the 27th Annual Milken Institute Global Conference

01 May 2024 07:00:00 By Nasdaq GlobeNewswire

Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)

29 Apr 2024 06:00:00 By Nasdaq GlobeNewswire

Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings

23 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates

01 Mar 2024 07:00:00 By Nasdaq GlobeNewswire